Alpha-Synuclein PET Tracer Development—An Overview about Current Efforts

Neurodegenerative diseases such as Parkinson’s disease (PD) are manifested by inclusion bodies of alpha-synuclein (α-syn) also called α-synucleinopathies. Detection of these inclusions is thus far only possible by histological examination of postmortem brain tissue. The possibility of non-invasively...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 14; no. 9; p. 847
Main Authors Korat, Špela, Bidesi, Natasha Shalina Rajani, Bonanno, Federica, Di Nanni, Adriana, Hoàng, Anh Nguyên Nhât, Herfert, Kristina, Maurer, Andreas, Battisti, Umberto Maria, Bowden, Gregory David, Thonon, David, Vugts, Daniëlle, Windhorst, Albert Dirk, Herth, Matthias Manfred
Format Journal Article Web Resource
LanguageEnglish
Published Basel MDPI AG 26.08.2021
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Neurodegenerative diseases such as Parkinson’s disease (PD) are manifested by inclusion bodies of alpha-synuclein (α-syn) also called α-synucleinopathies. Detection of these inclusions is thus far only possible by histological examination of postmortem brain tissue. The possibility of non-invasively detecting α-syn will therefore provide valuable insights into the disease progression of α-synucleinopathies. In particular, α-syn imaging can quantify changes in monomeric, oligomeric, and fibrillic α-syn over time and improve early diagnosis of various α-synucleinopathies or monitor treatment progress. Positron emission tomography (PET) is a non-invasive in vivo imaging technique that can quantify target expression and drug occupancies when a suitable tracer exists. As such, novel α-syn PET tracers are highly sought after. The development of an α-syn PET tracer faces several challenges. For example, the low abundance of α-syn within the brain necessitates the development of a high-affinity ligand. Moreover, α-syn depositions are, in contrast to amyloid proteins, predominantly localized intracellularly, limiting their accessibility. Furthermore, another challenge is the ligand selectivity over structurally similar amyloids such as amyloid-beta or tau, which are often co-localized with α-syn pathology. The lack of a defined crystal structure of α-syn has also hindered rational drug and tracer design efforts. Our objective for this review is to provide a comprehensive overview of current efforts in the development of selective α-syn PET tracers.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
scopus-id:2-s2.0-85114739447
ISSN:1424-8247
1424-8247
DOI:10.3390/ph14090847